ストックスクリーナーアプリを入手
150.85
1.07%
-1.645
前日終値:
$152.50
開ける：
$151.845
24時間の取引高:
3.71M
Relative Volume:
0.52
時価総額：
$187.13B
収益：
$29.05B
当期純損益:
$8.11B
株価収益率:
23.37
EPS:
6.4563
ネットキャッシュフロー:
$9.16B
1週間 パフォーマンス:
+5.59%
1か月 パフォーマンス:
+24.59%
6か月 パフォーマンス:
+26.35%
1年 パフォーマンス:
+57.10%
1日の値動き範囲:
$150.18
$153.00
1週間の範囲:
$142.03
$153.13
52週間の値動き範囲:
$93.37
$153.13
Gilead Sciences Inc Stock (GILD) Company Profile
Compare GILD vs LLY, JNJ, ABBV, NVS, AZN
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
150.83 | 189.20B | 29.05B | 8.11B | 9.16B | 6.4563 |
|
LLY
Lilly Eli Co
|
1,051.03 | 947.09B | 65.18B | 20.64B | 6.44B | 22.96 |
|
JNJ
Johnson Johnson
|
237.16 | 578.21B | 94.19B | 26.80B | 20.46B | 11.05 |
|
ABBV
Abbvie Inc
|
220.99 | 394.89B | 61.16B | 4.20B | 19.68B | 2.3671 |
|
NVS
Novartis Ag Adr
|
156.36 | 298.47B | 54.72B | 14.02B | 15.32B | 7.1855 |
|
AZN
Astrazeneca Plc
|
188.34 | 299.25B | 58.07B | 9.40B | 9.87B | 3.0115 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-01-07 | 再開されました | UBS | Buy |
| 2025-11-24 | 再開されました | Truist | Buy |
| 2025-11-13 | 開始されました | Scotiabank | Sector Outperform |
| 2025-08-19 | アップグレード | Daiwa Securities | Neutral → Outperform |
| 2025-08-08 | アップグレード | Truist | Hold → Buy |
| 2025-07-25 | アップグレード | Needham | Hold → Buy |
| 2025-04-22 | 再開されました | Cantor Fitzgerald | Overweight |
| 2025-03-04 | 繰り返されました | Oppenheimer | Outperform |
| 2025-02-18 | アップグレード | Deutsche Bank | Hold → Buy |
| 2025-02-13 | アップグレード | DZ Bank | Hold → Buy |
| 2025-01-10 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | 再開されました | BofA Securities | Buy |
| 2024-11-15 | 開始されました | Wolfe Research | Outperform |
| 2024-11-14 | 開始されました | Citigroup | Buy |
| 2024-11-08 | ダウングレード | Maxim Group | Buy → Hold |
| 2024-10-21 | アップグレード | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | 開始されました | Bernstein | Outperform |
| 2024-10-07 | アップグレード | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | アップグレード | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | 繰り返されました | Maxim Group | Buy |
| 2024-04-24 | アップグレード | HSBC Securities | Reduce → Hold |
| 2024-02-22 | ダウングレード | Truist | Buy → Hold |
| 2023-11-09 | 開始されました | Deutsche Bank | Hold |
| 2023-09-08 | アップグレード | BofA Securities | Neutral → Buy |
| 2023-09-06 | 開始されました | HSBC Securities | Reduce |
| 2023-07-24 | 繰り返されました | Barclays | Equal Weight |
| 2023-05-16 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | 再開されました | Piper Sandler | Overweight |
| 2023-01-03 | ダウングレード | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | 再開されました | BofA Securities | Neutral |
| 2022-12-09 | ダウングレード | DZ Bank | Buy → Hold |
| 2022-10-31 | アップグレード | Barclays | Underweight → Equal Weight |
| 2022-10-28 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2022-10-28 | 繰り返されました | Cowen | Outperform |
| 2022-10-28 | 繰り返されました | JP Morgan | Overweight |
| 2022-10-28 | 繰り返されました | Jefferies | Buy |
| 2022-10-28 | アップグレード | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-10-28 | アップグレード | Truist | Hold → Buy |
| 2022-10-28 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-10-04 | アップグレード | JP Morgan | Neutral → Overweight |
| 2022-07-13 | 開始されました | Cantor Fitzgerald | Neutral |
| 2022-05-23 | 開始されました | SVB Leerink | Mkt Perform |
| 2022-02-28 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | 繰り返されました | BMO Capital Markets | Outperform |
| 2022-02-02 | 繰り返されました | BofA Securities | Neutral |
| 2022-02-02 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2022-02-02 | 繰り返されました | Truist | Hold |
| 2022-02-02 | 繰り返されました | Wells Fargo | Equal Weight |
| 2022-01-28 | アップグレード | Argus | Hold → Buy |
| 2022-01-06 | ダウングレード | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | 再開されました | Wells Fargo | Equal Weight |
| 2021-12-06 | 開始されました | Goldman | Neutral |
| 2021-11-19 | アップグレード | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | 再開されました | Piper Sandler | Neutral |
| 2021-10-20 | 再開されました | Cowen | Outperform |
| 2021-07-30 | 繰り返されました | BMO Capital Markets | Market Perform |
| 2021-07-30 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2021-04-01 | アップグレード | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | アップグレード | Redburn | Neutral → Buy |
| 2021-01-19 | アップグレード | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | アップグレード | Guggenheim | Neutral → Buy |
| 2020-11-03 | 再開されました | Morgan Stanley | Equal-Weight |
| 2020-10-28 | 開始されました | UBS | Neutral |
| 2020-09-30 | 再開されました | Jefferies | Buy |
| 2020-09-15 | アップグレード | Maxim Group | Hold → Buy |
| 2020-07-31 | 繰り返されました | Credit Suisse | Neutral |
| 2020-07-31 | 繰り返されました | Morgan Stanley | Equal-Weight |
| 2020-07-31 | 繰り返されました | Piper Sandler | Overweight |
| 2020-07-31 | 繰り返されました | RBC Capital Mkts | Outperform |
| 2020-07-31 | 繰り返されました | SunTrust | Hold |
| 2020-07-31 | 繰り返されました | Wells Fargo | Equal Weight |
| 2020-07-20 | アップグレード | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | アップグレード | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | アップグレード | SunTrust | Sell → Hold |
| 2020-05-01 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2020-05-01 | ダウングレード | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | ダウングレード | SunTrust | Hold → Sell |
| 2020-04-27 | ダウングレード | UBS | Buy → Neutral |
| 2020-04-20 | ダウングレード | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | ダウングレード | CFRA | Hold → Sell |
すべてを表示
Gilead Sciences Inc (GILD) 最新ニュース
Gilead Sciences (GILD) Poised for Q4 Earnings Beat Amid Strong D - GuruFocus
Gilead Q4 preview: Core portfolio, Yeztugo launch keep analysts optimistic ahead of earnings - Seeking Alpha
Will These 5 Drug Bigwigs Surpass Q4 Earnings Forecasts? - TradingView
Should you buy Gilead Sciences before Feb. 10? - MSN
Should You Buy Gilead Sciences Before Feb. 10? - The Motley Fool
Exploring Gilead Sciences's Earnings Expectations - Benzinga
Candriam S.C.A. Has $179.86 Million Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Sold by ProShare Advisors LLC - MarketBeat
Alps Advisors Inc. Increases Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Reports Q4: Everything You Need To Know Ahead Of Earnings - Yahoo! Finance Canada
Early Trading Movement | Gilead Sciences-B Shares Surge Over 7%, With the 5-day MA Crossing Above the 10-day MA to Form a Golden Cross - 富途牛牛
Gilead stock at 52-week high after FDA Yescarta label change, with earnings next - TechStock²
Plato Investment Management Ltd Acquires 6,668 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences (GILD) Is Up 7.4% After FDA Expands Yescarta Lymphoma Label Restrictions Removed - simplywall.st
Canada Post Corp Registered Pension Plan Has $11.64 Million Position in Gilead Sciences, Inc. $GILD - MarketBeat
Assessing Gilead Sciences (GILD) Valuation After Its Strong Recent Share Price Performance - Yahoo Finance
Gilead Sciences (NASDAQ:GILD) CEO Daniel Patrick O'day Sells 115,640 Shares - MarketBeat
Gilead Sciences CEO O’Day sells $17.3 million in stock - Investing.com
Gilead Sciences CEO O’Day sells $17.3 million in stock By Investing.com - Investing.com India
Biopharma bites: Dosing pause for uniQure's gene therapy, EU OK for GSK's Nucala, and a label update for Gilead's CAR-T - FirstWord Pharma
Gilead’s Dietmar Berger Reflects On Pipeline After First Year As CMO - Citeline News & Insights
Gilead is advertising around the Super Bowl to get out the word about new HIV-prevention drug - The Business Journals
Is Gilead Sciences (GILD) a 'Buy' Ahead of Its Upcoming Earnings Announcement? - Yahoo Finance
Gilead (GILD) Gains FDA Nod for Expanded Use of Yescarta in Lymp - GuruFocus
FDA Updates Yescarta Label, Boosts Gilead's (GILD) Market Positi - GuruFocus
Gilead wins favorable FDA label update for Yescarta (GILD) - Seeking Alpha
Gilead Sciences Says Yescarta Won FDA Label Update, Removing Use Limits for Relapsed CNS Lymphoma Patients - marketscreener.com
Gilead Sciences (GILD) Valuation Check After Oncology And HIV Therapy Momentum - simplywall.st
J.W. Cole Advisors Inc. Purchases 7,397 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Envestnet Asset Management Inc. Lowers Stock Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Is Gilead Sciences (GILD) Still Attractive After Strong Multi‑Year Share Price Gains - Yahoo Finance
Ahead of Gilead (GILD) Q4 Earnings: Get Ready With Wall Street Estimates for Key Metrics - Yahoo Finance
Gilead Sciences, Inc. (GILD): A bull case theory - MSN
Ashton Thomas Private Wealth LLC Acquires 10,107 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Stock Holdings Increased by Jones Financial Companies Lllp - MarketBeat
Machina Capital S.A.S. Makes New $1.65 Million Investment in Gilead Sciences, Inc. $GILD - MarketBeat
ABN AMRO Bank N.V. Acquires Shares of 46,091 Gilead Sciences, Inc. $GILD - MarketBeat
BI Asset Management Fondsmaeglerselskab A S Sells 60,982 Shares of Gilead Sciences, Inc. $GILD - MarketBeat
Gilead Sciences, Inc. $GILD Shares Purchased by AGF Management Ltd. - MarketBeat
Gilead Sciences (GILD) Rises As Market Takes a Dip: Key Facts - Yahoo Finance
Gilead Sciences Stock Surged 50%, Here's Why - Trefis
This Overlooked Biotech Giant Could Surprise Investors This Quarter - Barchart.com
Here's Why Gilead Sciences Stock Surged 21% in a Month - Finviz
Earnings Preview: Gilead Sciences (GILD) Q4 Earnings Expected to Decline - Yahoo Finance
Gilead Sciences (GILD) to Release Quarterly Earnings on Tuesday - MarketBeat
Principal Financial Group Inc. Trims Holdings in Gilead Sciences, Inc. $GILD - MarketBeat
Targeted Cancer Therapy Market to Reach US$ 175.48 Billion by 2035 Driven by Precision Oncology Adoption, ADC Innovation, and Regulatory Productivity Says Astute Analytica - GlobeNewswire Inc.
Gilead Sciences Oncology Push Gains Traction With Trodelvy Keytruda Results - Yahoo Finance
Gilead’s Growing Oncology Role Reshapes The Investment Case For GILD - simplywall.st
Gilead Sciences, Inc. (GILD): A Bull Case Theory - Finviz
Implied Volatility Surging for Gilead Sciences Stock Options - Yahoo Finance
Gilead Sciences Inc (GILD) 財務データ
収益
当期純利益
現金流量
EPS
Gilead Sciences Inc (GILD) インサイダートレーディング
| インサイダートレーディング | 関係 | 日付 | 取引 | コスト | #株式 | 値 ($) | #株式総数 |
|---|---|---|---|---|---|---|---|
| O'Day Daniel Patrick | Chairman & CEO |
Feb 05 '26 |
Sale |
150.00 |
115,640 |
17,346,000 |
613,912 |
2.53%
3.57%
大文字化:
|
ボリューム (24 時間):